Combined Palbociclib and Endocrine Therapy Found to Suppress Adaptive Immunity in Early Breast Cancer Patients

The NeoRHEA phase 2 study has identified significant effects of combined palbociclib and endocrine therapy on the adaptive immune response in early breast cancer patients. Researchers, including Papagiannis, Majjaj, and Duhoux, found that this treatment regimen substantially reduces anti-tumor immunity. The findings highlight a notable interaction between therapeutic approaches and the body’s immune system in managing breast cancer.

The study examined how palbociclib, a cyclin-dependent kinase inhibitor often used alongside endocrine therapy to treat hormone receptor-positive breast cancer, impacts the immune system’s ability to combat tumors. Results showed that the combination therapy suppresses adaptive immunity, which plays a critical role in identifying and attacking cancer cells. These findings provide new information about the potential implications of widely-used treatments on immune function in breast cancer patients.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 26, 2025

Related posts:

DrugPatentWatch Guide Explores Data-Driven Strategies to Maximize Pharmaceutical Pricing ROI Mice Perceive Artificial Limb as Part of Their Body in Study Published in PLOS Biology Immune Cells in the Brain Influence Frontal Cortex Development During Adolescence Doctor Mike Advocates for Social Media Engagement to Combat Misinformation and Rebuild Trust in Public Health Institutions

Author

GOAI